Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2003 1
2004 1
2006 2
2007 2
2009 1
2011 2
2012 1
2016 1
2018 3
2019 1
2020 3
2021 3
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Rascol O, et al. Parkinsonism Relat Disord. 2022 Mar;96:65-73. doi: 10.1016/j.parkreldis.2022.01.022. Epub 2022 Feb 8. Parkinsonism Relat Disord. 2022. PMID: 35227940 Free article. Clinical Trial.
[Guidelines for the treatment of spasticity in adults using Botulinum toxin].
Aguilar-Barberá M, Bori-Fortuny I, García-Aymerich V, García-Ruiz Espiga PJ, Garreta-Figuera R, Herrera-Galante A, Lanzas-Melendo G, de Miguel-León I, Miquel-Rodríguez F, Pascual-Pascual SI, Póo P, Vivancos-Matellano F. Aguilar-Barberá M, et al. Among authors: vivancos matellano f. Rev Neurol. 2004 May 16-31;38(10):971-8. Rev Neurol. 2004. PMID: 15175981 Free article. Review. Spanish.
Spanish expert consensus on the use of safinamide in Parkinson's disease.
Valldeoriola F, Grandas F, Arbelo JM, Blázquez Estrada M, Calopa Garriga M, Campos-Arillo VM, Garcia Ruiz PJ, Gómez Esteban JC, Leiva Santana C, Martínez Castrillo JC, Mir P, Salvador Aliaga A, Vivancos Matellano F, Yáñez Baña RM. Valldeoriola F, et al. Among authors: vivancos matellano f. Neurologia (Engl Ed). 2021 Nov-Dec;36(9):666-672. doi: 10.1016/j.nrleng.2018.04.004. Epub 2020 May 29. Neurologia (Engl Ed). 2021. PMID: 34752344 Free article.
Assessment of Parkinson disease: what do we need to show neuroprotection?
Ybot-Gorrin I, Vivancos-Matellano F, Chacón-Peña JR, Alonso-Navarro H, Jiménez-Jiménez FJ. Ybot-Gorrin I, et al. Among authors: vivancos matellano f. Neurologist. 2011 Nov;17(6 Suppl 1):S21-9. doi: 10.1097/NRL.0b013e31823966c6. Neurologist. 2011. PMID: 22045322 Review.
Spanish expert consensus on the use of safinamide in Parkinson's disease.
Valldeoriola F, Grandas F, Arbelo JM, Blázquez Estrada M, Calopa Garriga M, Campos-Arillo VM, Garcia Ruiz PJ, Gómez Esteban JC, Leiva Santana C, Martínez Castrillo JC, Mir P, Salvador Aliaga A, Vivancos Matellano F, Yáñez Baña RM. Valldeoriola F, et al. Among authors: vivancos matellano f. Neurologia (Engl Ed). 2018 Jul 30:S0213-4853(18)30172-5. doi: 10.1016/j.nrl.2018.04.007. Online ahead of print. Neurologia (Engl Ed). 2018. PMID: 30072274 Free article. English, Spanish.
Validation of the OPTIMIPARK Questionnaire: A Tool to Optimize Treatment in Parkinson's Disease.
Máñez-Miró JU, Vivancos-Matellano F, Alonso-Frech F, Vela-Desojo L, López-Ariztegui N, López-Manzanares L, Balaguer E, Martínez-Castrillo JC, Herrero-Infante Y, Gasca-Salas C, Morales-Casado MI, Casas E, Hernández A, Pareés I, Tegel-Ayuela I, Martínez-Fernández R, Martinez-Martin P. Máñez-Miró JU, et al. Among authors: vivancos matellano f. Mov Disord Clin Pract. 2022 Oct 18;9(8):1085-1093. doi: 10.1002/mdc3.13581. eCollection 2022 Nov. Mov Disord Clin Pract. 2022. PMID: 36339297 Free PMC article.
21 results